Literature DB >> 23086181

Central nervous system demyelinating diseases and recombinant hepatitis B vaccination: a critical systematic review of scientific production.

V Martínez-Sernández1, A Figueiras.   

Abstract

The etiology of multiple sclerosis has not yet been fully described. A potential link between the recombinant hepatitis B vaccine and an increased risk of onset or exacerbation of multiple sclerosis emerged in the mid-1990s, leading to several spontaneous reports and studies investigating this association. We conducted a critical systematic review aimed at assessing whether hepatitis B vaccination increases the risk of onset or relapse of multiple sclerosis and other central nervous system demyelinating diseases. MEDLINE and EMBASE were used as data sources, and the search covered the period between 1981 and 2011. Twelve references met the inclusion criteria. No significant increased risk of onset or relapse of the diseases considered was associated with hepatitis B vaccination, except in one study. Most studies included in this review displayed methodological limitations and heterogeneity among them, which rendered it impossible to draw robust conclusions about the safety of hepatitis B vaccination in healthy subjects and patients with multiple sclerosis. Therefore, on the basis of current data there is no need to modify the vaccination recommendations; however, there is a need to improve the quality of observational studies with emphasis on certain considerations that are discussed in this review.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23086181     DOI: 10.1007/s00415-012-6716-y

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  41 in total

1.  Vaccinations and multiple sclerosis.

Authors:  B Bégaud; A Alpérovitch
Journal:  N Engl J Med       Date:  2001-06-07       Impact factor: 91.245

2.  Vaccinations and multiple sclerosis.

Authors:  O Gout
Journal:  N Engl J Med       Date:  2001-06-07       Impact factor: 91.245

Review 3.  Could autoimmunity be induced by vaccination?

Authors:  Simonetta Salemi; Raffaele D'Amelio
Journal:  Int Rev Immunol       Date:  2010-06       Impact factor: 5.311

4.  A case-control study of serious autoimmune adverse events following hepatitis B immunization.

Authors:  David A Geier; Mark R Geier
Journal:  Autoimmunity       Date:  2005-06       Impact factor: 2.815

5.  [The first episode of central nervous system demyelinization and hepatitis B virus vaccination].

Authors:  E Touzé; O Gout; M H Verdier-Taillefer; O Lyon-Caen; A Alpérovitch
Journal:  Rev Neurol (Paris)       Date:  2000-03       Impact factor: 2.607

6.  Hepatitis B vaccination and the risk of multiple sclerosis.

Authors:  A Ascherio; S M Zhang; M A Hernán; M J Olek; P M Coplan; K Brodovicz; A M Walker
Journal:  N Engl J Med       Date:  2001-02-01       Impact factor: 91.245

Review 7.  Autoimmune diseases and vaccinations.

Authors:  Thierry Vial; Jacques Descotes
Journal:  Eur J Dermatol       Date:  2004 Mar-Apr       Impact factor: 3.328

8.  Hepatitis B vaccine and the risk of CNS inflammatory demyelination in childhood.

Authors:  Yann Mikaeloff; Guillaume Caridade; Samy Suissa; Marc Tardieu
Journal:  Neurology       Date:  2008-10-08       Impact factor: 9.910

9.  Hepatitis B vaccination and the risk of childhood-onset multiple sclerosis.

Authors:  Yann Mikaeloff; Guillaume Caridade; Mélanie Rossier; Samy Suissa; Marc Tardieu
Journal:  Arch Pediatr Adolesc Med       Date:  2007-12

10.  A study of molecular mimicry and immunological cross-reactivity between hepatitis B surface antigen and myelin mimics.

Authors:  Dimitrios-Petrou Bogdanos; Heather Smith; Yun Ma; Harold Baum; Giorgina Mieli-Vergani; Diego Vergani
Journal:  Clin Dev Immunol       Date:  2005-09
View more
  10 in total

Review 1.  [Multiple sclerosis and hepatitis B vaccination : What does the verdict of the European Court of Justice on liability after vaccination mean?]

Authors:  M Löbermann; B Handorn; A Winkelmann; E C Reisinger; H P Hartung; U K Zettl
Journal:  Nervenarzt       Date:  2018-10       Impact factor: 1.214

Review 2.  Vaccines in Multiple Sclerosis.

Authors:  Eric M L Williamson; Salim Chahin; Joseph R Berger
Journal:  Curr Neurol Neurosci Rep       Date:  2016-04       Impact factor: 5.081

Review 3.  Prevention of hepatitis B.

Authors:  Mei-Hwei Chang; Ding-Shinn Chen
Journal:  Cold Spring Harb Perspect Med       Date:  2015-03-02       Impact factor: 6.915

4.  HBV vaccine and risk of developing multiple sclerosis: a systematic review and meta-analysis.

Authors:  Cristina Sestili; Inês Grazina; Giuseppe La Torre
Journal:  Hum Vaccin Immunother       Date:  2021-07-03       Impact factor: 4.526

5.  Seronegative Neuromyelitis Optica Spectrum Disorder following Exposure to Hepatitis B Vaccination.

Authors:  Richard Heekin; Chetan Gandhy; Derrick Robertson
Journal:  Case Rep Neurol       Date:  2015-04-11

6.  IT Infrastructure to support the secondary use of routinely acquired clinical imaging data for research.

Authors:  Kai Yan Eugene Leung; Fedde van der Lijn; Henri A Vrooman; Miriam C J M Sturkenboom; Wiro J Niessen
Journal:  Neuroinformatics       Date:  2015-01

Review 7.  Vaccination in Multiple Sclerosis: Friend or Foe?

Authors:  Tobias Zrzavy; Herwig Kollaritsch; Paulus S Rommer; Nina Boxberger; Micha Loebermann; Isabella Wimmer; Alexander Winkelmann; Uwe K Zettl
Journal:  Front Immunol       Date:  2019-08-07       Impact factor: 7.561

Review 8.  Applications of nanotechnology for immunology.

Authors:  Douglas M Smith; Jakub K Simon; James R Baker
Journal:  Nat Rev Immunol       Date:  2013-08       Impact factor: 53.106

Review 9.  Vaccination of Adult Patients with Systemic Lupus Erythematosus in Portugal.

Authors:  Maria Francisca Moraes-Fontes; Ana Margarida Antunes; Heidi Gruner; Nuno Riso
Journal:  Int J Rheumatol       Date:  2016-03-16

10.  Hepatitis B vaccine adverse events in China: risk control and regulation.

Authors:  Li Meina; Liu Xiaodong; Zhang Lulu
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.